Atopix is focused on the development of new medicines to treat Th2 mediated eosinophilic asthma.
Allergic disease includes common conditions such as asthma and associated conditions such as allergic rhinitis.
Th2 lymphocytes and innate lymphoid cells (ILCs) both play a central role in the pathogenesis of eosinophilic disease. These cells respond to allergic and non-allergic stimuli by secreting key cytokines that have a proven role in asthma and related conditions.
Atopix is targeting an important receptor molecule known as CRTH2 present on the surface of Th2 lymphocytes, type 2 ILCs, eosinophils and basophils.
Blocking this receptor interferes with initiation and maintenance of Th2 responses and has been shown to reduce the symptoms of disease. Because this approach is exquisitely specific for the Th2 arm of the immune system, it can achieve this without the risk of widespread immunosuppression that is characteristic of systemic steroids or calcineurin inhibitors (cyclosporines).
Atopix has two lead products, timapiprant and ATX2417, both CRTH2 antagonists, supported by a pipeline of back-up candidates.